Skip to main content
. 2024 Feb 5;2024(2):CD015219. doi: 10.1002/14651858.CD015219.pub2

Balykova 2020.

Study characteristics
Methods Open‐label RCT
Participants Inpatients; confirmed COVID‐19 (moderate)
Interventions Favipiravir, standard of care
Outcomes Time to clinical recovery, mortality, progression to invasive mechanical ventilation, significant changes in vital signs and clinical laboratory parameters, adverse events and serious adverse events, adverse events leading to drug discontinuation, and progression to non‐invasive ventilation
Notes